Sutro Biopharma, Inc.
Clinical trials sponsored by Sutro Biopharma, Inc., explained in plain language.
A biopharmaceutical company developing next-generation antibody-drug conjugates and immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Experimental ovarian cancer drug combo studied in early trial
Disease control Stopped earlyThis early-phase trial tested a new drug called STRO-002 combined with Avastin (bevacizumab) in 58 people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The main goals were to check safety and find the right dose. The study was terminated early, so while it …
Phase 1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for tough ovarian cancer? trial tests smart drug vs chemo
Disease control Stopped earlyThis study tested a new drug called luveltamab tazevibulin (STRO-002) against standard chemotherapy in 600 women with ovarian cancer that had stopped responding to platinum treatment. The drug targets a protein (FOLR1) found on many ovarian cancer cells. The trial was terminated …
Phase 2/3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC